{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:18:04Z","timestamp":1780597084936,"version":"3.54.1"},"reference-count":15,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T00:00:00Z","timestamp":1498521600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T00:00:00Z","timestamp":1498521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1111\/jcpt.12582","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T04:56:58Z","timestamp":1498625818000},"page":"104-106","source":"Crossref","is-referenced-by-count":7,"title":["Dosing considerations in the use of the direct oral anticoagulants in the antiphospholipid syndrome"],"prefix":"10.1155","volume":"43","author":[{"given":"J. R.","family":"Schofield","sequence":"first","affiliation":[{"name":"University of Colorado at Denver - Anschutz Medical Campus; Aurora CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hassell","sequence":"additional","affiliation":[{"name":"University of Colorado at Denver - Anschutz Medical Campus; Aurora CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2017,6,27]]},"reference":[{"key":"10.1111\/jcpt.12582-BIB0001|jcpt12582-cit-0001","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/kev445","article-title":"Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome","volume":"55","author":"Sciascia","year":"2016","journal-title":"Rheum"},{"key":"10.1111\/jcpt.12582-BIB0002|jcpt12582-cit-0002","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1111\/jcpt.12582-BIB0003|jcpt12582-cit-0003","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10067-015-3030-y","article-title":"Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases","volume":"35","author":"Signorelli","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1111\/jcpt.12582-BIB0004|jcpt12582-cit-0004","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ajh.23797","article-title":"New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome","volume":"89","author":"Win","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1111\/jcpt.12582-BIB0005|jcpt12582-cit-0005","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa013383","article-title":"Skin ulcers misdiagnosed as pyoderma gangrenosum","volume":"347","author":"Weenig","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12582-BIB0006|jcpt12582-cit-0006","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/RHU.0b013e3180690af6","article-title":"Dramatic response of severe headaches to anticoagulation in a patient with antiphospholipid syndrome","volume":"13","author":"Asherson","year":"2007","journal-title":"J Clin Rheumatol"},{"key":"10.1111\/jcpt.12582-BIB0007|jcpt12582-cit-0007","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1177\/096120330101001103","article-title":"Headache and memory loss: rapid response to heparin in the antiphospholipid syndrome","volume":"10","author":"Hughes","year":"2001","journal-title":"Lupus"},{"key":"10.1111\/jcpt.12582-BIB0008|jcpt12582-cit-0008","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0961203312451336","article-title":"Heparin, antiphospholipid antibodies and the brain","volume":"21","author":"Hughes","year":"2012","journal-title":"Lupus"},{"key":"10.1111\/jcpt.12582-BIB0009|jcpt12582-cit-0009","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/10446670410001670526","article-title":"Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model","volume":"11","author":"Ziporen","year":"2004","journal-title":"Clin Dev Immunol"},{"key":"10.1111\/jcpt.12582-BIB0010|jcpt12582-cit-0010","first-page":"179","article-title":"A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban","volume":"6","author":"Frost","year":"2014","journal-title":"Clin Pharmacol"},{"key":"10.1111\/jcpt.12582-BIB0011|jcpt12582-cit-0011","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bcp.12106","article-title":"Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects","volume":"76","author":"Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12582-BIB0012|jcpt12582-cit-0012","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/0003-4819-134-3-200102060-00009","article-title":"Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease","volume":"134","author":"Merli","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1111\/jcpt.12582-BIB0013|jcpt12582-cit-0013","doi-asserted-by":"crossref","first-page":"i5549","DOI":"10.1136\/bmj.i5549","article-title":"Optimal dosing of rivaroxaban is undefined","volume":"355","author":"Moore","year":"2016","journal-title":"BMJ"},{"key":"10.1111\/jcpt.12582-BIB0014|jcpt12582-cit-0014","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.phrs.2017.03.026","article-title":"Emerging therapeutic uses of direct-acting oral anticoagulants: an evidence-based perspective","volume":"120","author":"Raschi","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1111\/jcpt.12582-BIB0015|jcpt12582-cit-0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1076029615615960","article-title":"Apixaban for the Secondary Prevention of Thrombosis Among Patients with Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS)","volume":"22","author":"Woller","year":"2016","journal-title":"Clin Appl Thromb Hemost"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12582","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12582\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:03:08Z","timestamp":1671818588000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,27]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12582","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6,27]]}}}